Articles and analysis on Venture Capital Trusts (VCTs), the investment vehicles designed to provide individual investors with access to venture capital investments while offering tax incentives.


IBIS prepares for take-off

Former EMAP boss Sir Robin Miller heads the team behind two new venture capital trusts conceived to support small UK-based media companies.


Plastics play for Octopus

Octopus Asset Management, which runs the Eclipse series of VCTs, has supported acquisitive plastics manufacturer Plastics Capital, investing £3.1 million alongside City broker Investec.


Quester’s flu boost

A company in which technology specialist VCT manager Quester has invested stands to receive a boost from rising fears over a possible Avian flu outbreak. The investment group backed PowderMed via the Isis College Fund it manages, in an initial £20 million fundraising in May 2004.


Murray 4 takes AIM

Murray 4 VCT, the only trust in this series still managed by Aberdeen Murray Johnstone Private Equity, is increasing its AIM investment activities.


Sweet Nectar for ProVen

Beringea, which manages the two ProVen VCTs, has managed to more than double its money on an investment in community pub owner Nectar Taverns, following the company's sale to Lincoln Capital.


Octopus launches twin trusts

Octopus Asset Management, the operator of four venture capital trusts – namely, Eclipse 1 and 2, BioScience and Phoenix VCT – has revealed it is seeking to raise up to £60 million through a new twin investment vehicle.


Roche snaps up Glycart

Pharmaceutical giant Roche has boosted returns significantly at technology fund manager Quester by taking over portfolio company GlycArt for £104 million.


Close makes maiden investments

Close Income & Growth VCT, the most popular of the forty or so trusts seeking funds in the last tax year, has started to invest the £45 million cash pile it gathered in earlier this year.

Venture Capital Funding

VCs with money to burn

The venture capital markets are awash with record levels of cash, which is good news for growing companies in need of funding. But the bad news is that investors are being more picky than ever before.


Grosvenor receives healthy support

Occupational health services provider Grosvenor Healthcare has receivedan additional £1.05 million from existing investor Close VentureManagement to fund the acquisition of Glasgow rival Associated HealthSpecialists.


Bioscience breaches VCT rules

Octopus Asset Management has admitted that the Bioscience VCT it manages will breach the VCT rules.


ProVen pulls fundraising

The crowded VCT fundraising market has seen its first casualty after Beringea, which manages the ProVen and ProVen Media VCTs, pulled its £30 million fundraising for ProVen 3.